Ani Pharmaceuticals (ANIP) Cost of Revenue (2012 - 2026)
Ani Pharmaceuticals (ANIP) posted Cost of Revenue of $93.6 million for Q1 2026, down 6.67% sequentially from $100.3 million in Q4 2025, and up 28.13% YoY from $73.0 million in Q1 2025.
Ani Pharmaceuticals (ANIP) Cost of Revenue (2012 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported Cost of Revenue for 15 years, with the latest figure at $93.6 million in Q1 2026.
- Quarterly Cost of Revenue rose 28.13% year-over-year to $93.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $361.9 million (up 32.02% YoY) and the FY2025 annual result came in at $341.3 million, up 36.41% from the prior year.
- Cost of Revenue retreated to $93.6 million in Q1 2026 per ANIP's latest filing, from $100.3 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $100.3 million in Q4 2025 and troughed at $32.9 million in Q3 2022.
- A 5-year average of $59.1 million and a median of $53.4 million in 2023 frame the typical range for Cost of Revenue.
- The widest YoY moves for Cost of Revenue: up 71.48% in 2022, down 7.16% in 2022.
- Over 5 years, Cost of Revenue stood at $36.3 million in 2022, then jumped by 47.06% to $53.4 million in 2023, then soared by 50.28% to $80.3 million in 2024, then grew by 24.9% to $100.3 million in 2025, then decreased by 6.67% to $93.6 million in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $93.6 million, $100.3 million, and $93.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn | 100.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100.16 Mn |
| Jun 30, 2026 | 100.16 Mn |
| Mar 31, 2026 | 93.58 Mn |
| Mar 31, 2026 | 93.58 Mn |
| Dec 31, 2025 | 100.27 Mn |
| Dec 31, 2025 | 100.27 Mn |
| Sep 30, 2025 | 93.39 Mn |
| Sep 30, 2025 | 93.39 Mn |
| Jun 30, 2025 | 74.62 Mn |
| Jun 30, 2025 | 74.62 Mn |
| Mar 31, 2025 | 73.04 Mn |
| Mar 31, 2025 | 73.04 Mn |
| Dec 31, 2024 | 80.28 Mn |
| Dec 31, 2024 | 80.28 Mn |
| Sep 30, 2024 | 63.08 Mn |
| Sep 30, 2024 | 63.08 Mn |
| Jun 30, 2024 | 57.70 Mn |
| Jun 30, 2024 | 57.70 Mn |
| Mar 31, 2024 | 49.16 Mn |
| Mar 31, 2024 | 49.16 Mn |